Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Apr 28, 2026, 01:32Spencer Knight: Breakthrough in Gene Therapy – Life-Changing Vision Restored for Young Girl
-
Apr 28, 2026, 01:24Laurel Brumant-Palmer: Strength in Community – Celebrating Sickle Cell Resilience at Soho
-
Apr 28, 2026, 01:17Ney Carter Borges: Triple Low-Dose Antihypertensive Therapy After Intracerebral Hemorrhage – A Pragmatic and Effective Strategy
-
Apr 27, 2026, 23:24Leonardo Roever: The Emerging Role of the TyHGB Index in Predicting New-Onset Stroke
-
Apr 27, 2026, 20:25Shek Sady Khan: Addressing the Silent Burden of Venous Thromboembolism in Bangladesh
-
Apr 27, 2026, 16:04Heghine Khachatryan: Intracranial Hemorrhage in Leukemia – Beyond Thrombocytopenia
-
Apr 27, 2026, 15:56Marc Carrier: Supporting Thrombosis Canada in My Final Year as President
-
Apr 27, 2026, 15:52Tagreed Alkaltham։ You Think Eligibility Is About You… It’s Not
-
Apr 27, 2026, 15:52Emma Gasson: Top Abstract Oral Presentation at BSH 2026 on Cancer-Associated Thrombosis Microfluidics